Want to join the conversation?
The generic drugmaker $MYL reported a fall in 3Q15 earnings due to higher operating expenses and tax benefit recorded in the previous year quarter on merger of its units into Mylan Labs. Net earnings fell to $428.6MM or $0.83 per share from $499.1MM or $1.26 per share last year. Revenue grew to $2.7Bil from $2.08Bil. Adjusted EPS grew 23% to $1.43.
$TXMD flying high.. anyone here to catch..?
$CMG crashing. There seems to be nothing good to read about this company.
Impressed with $AMZN’s latest grocery ambitions. The new Amazon Go convenience store, is an absolute game changer.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$